Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2012 1
2016 1
2017 1
2019 14
2020 16
2021 9
2022 5
2023 7
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: Meta-Analysis, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Tagraxofusp.
[No authors listed] [No authors listed] 2019 Jan 7. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2019 Jan 7. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30694624 Free Books & Documents. Review.
No information is available on the use of tagraxofusp during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during tagraxofusp therapy and for 1 week after the final dose....
No information is available on the use of tagraxofusp during breastfeeding. The manufacturer recommends that breastfeeding be discont …
Tagraxofusp.
[No authors listed] [No authors listed] 2019 Apr 12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2019 Apr 12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643455 Free Books & Documents. Review.
Tagraxofusp is a recombinant fusion protein consisting of the binding site of interleukin 3 [IL3] fused with diphtheria toxin and that is given by intravenous infusion and used as an antineoplastic agent for patients with blastic plasmacytoid dendritic cell neoplasm. Treat …
Tagraxofusp is a recombinant fusion protein consisting of the binding site of interleukin 3 [IL3] fused with diphtheria toxin and tha …
Tagraxofusp in myeloid malignancies.
Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, Neri A, Imovilli A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Hematol Oncol. 2024 Jan;42(1):e3234. doi: 10.1002/hon.3234. Epub 2023 Oct 17. Hematol Oncol. 2024. PMID: 37846131 Review.
It has been discovered that azacitidine can reverse DHP1 expression and restore sensitivity to tagraxofusp. In conclusion, the success of tagraxofusp in BPDCN paved the way for its application even in other CD123-positive malignancies. Nowadays, several ongoing tria …
It has been discovered that azacitidine can reverse DHP1 expression and restore sensitivity to tagraxofusp. In conclusion, the succes …
Tagraxofusp: First Global Approval.
Syed YY. Syed YY. Drugs. 2019 Apr;79(5):579-583. doi: 10.1007/s40265-019-01087-z. Drugs. 2019. PMID: 30859413 Review.
Tagraxofusp (tagraxofusp-erzs) [Elzonris] is an intravenously administered CD123-directed cytotoxin (composed of human interleukin-3 and a truncated diphtheria toxin payload) that was developed by Stemline Therapeutics, Inc. for the treatment of blastic plasmacytoid …
Tagraxofusp (tagraxofusp-erzs) [Elzonris] is an intravenously administered CD123-directed cytotoxin (composed of human interle …
Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Hammond D, Pemmaraju N. Hammond D, et al. Hematol Oncol Clin North Am. 2020 Jun;34(3):565-574. doi: 10.1016/j.hoc.2020.01.005. Epub 2020 Mar 18. Hematol Oncol Clin North Am. 2020. PMID: 32336420 Review.
Tagraxofusp, a CD123-targeted immunotoxin, is the first FDA-approved treatment for patients 2 years and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN). ...Given the risk of potentially fatal capillary leak syndrome with tagraxofusp, judicious patien …
Tagraxofusp, a CD123-targeted immunotoxin, is the first FDA-approved treatment for patients 2 years and older with blastic plasmacyto …
Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
Lee SS, McCue D, Pemmaraju N. Lee SS, et al. Expert Rev Anticancer Ther. 2020 Jul;20(7):543-550. doi: 10.1080/14737140.2020.1776120. Epub 2020 Jun 24. Expert Rev Anticancer Ther. 2020. PMID: 32460559 Review.
AREAS COVERED: We discuss the history and clinical background of BPDCN along with tagraxofusp as its first-line therapy. We review the clinical efficacy and safety profile of tagraxofusp in adults including proposed sensitivity and resistance. Finally, we summarize …
AREAS COVERED: We discuss the history and clinical background of BPDCN along with tagraxofusp as its first-line therapy. We review th …
Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
Luskin MR, Lane AA. Luskin MR, et al. Haematologica. 2024 Jan 1;109(1):44-52. doi: 10.3324/haematol.2022.282171. Haematologica. 2024. PMID: 36951152 Free PMC article. Review.
Tagraxofusp treatment is associated with a unique toxicity, capillary leak syndrome (CLS), which can be severe but is manageable with proper patient selection and monitoring, early recognition, and directed intervention. We outline our approach to the use of tagraxofusp …
Tagraxofusp treatment is associated with a unique toxicity, capillary leak syndrome (CLS), which can be severe but is manageable with …
Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.
Tandon A, Zhang Y, Sokol L. Tandon A, et al. Drugs Today (Barc). 2019 Dec;55(12):735-742. doi: 10.1358/dot.2019.55.12.3058917. Drugs Today (Barc). 2019. PMID: 31942876 Review.
Tagraxofusp is a toxin-cytokine fusion protein consisting of engineered diphtheria toxin (DT) and interleukin-3 (IL-3). ...In this review, we examine the preclinical studies and phase I/II clinical studies that led to FDA approval of tagraxofusp, focusing on its mol …
Tagraxofusp is a toxin-cytokine fusion protein consisting of engineered diphtheria toxin (DT) and interleukin-3 (IL-3). ...In this re …
Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Alfayez M, Konopleva M, Pemmaraju N. Alfayez M, et al. Expert Opin Biol Ther. 2020 Feb;20(2):115-123. doi: 10.1080/14712598.2020.1701651. Epub 2019 Dec 17. Expert Opin Biol Ther. 2020. PMID: 31801379 Review.
Introduction: Advances and drug development in rare diseases, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN), has historically been limited by small numbers of patients in the target population. In recent years, the development of tagraxofusp (SL-401) (ELZONR …
Introduction: Advances and drug development in rare diseases, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN), has historically …
Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.
Economides MP, McCue D, Lane AA, Pemmaraju N. Economides MP, et al. Expert Rev Clin Pharmacol. 2019 Oct;12(10):941-946. doi: 10.1080/17512433.2019.1662297. Epub 2019 Oct 1. Expert Rev Clin Pharmacol. 2019. PMID: 31465247 Review.
Areas Covered: In this review, we discuss the use of tagraxofusp in BPDCN, and active clinical trials involving this agent in several hematologic malignancies are also presented. ...Many patients treated with this agent were able to be bridged to stem cell transplantation, …
Areas Covered: In this review, we discuss the use of tagraxofusp in BPDCN, and active clinical trials involving this agent in several …
55 results